These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 32631286)

  • 1. Markers of potassium homeostasis in salt losing tubulopathies- associations with hyperaldosteronism and hypomagnesemia.
    Eder M; Darmann E; Haller MC; Bojic M; Peck-Radosavljevic M; Huditz R; Bond G; Vychytil A; Reindl-Schwaighofer R; Kikić Ž
    BMC Nephrol; 2020 Jul; 21(1):256. PubMed ID: 32631286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies on the pathogenesis of hypokalemia in Gitelman's syndrome: role of bicarbonaturia and hypomagnesemia.
    Kamel KS; Harvey E; Douek K; Parmar MS; Halperin ML
    Am J Nephrol; 1998; 18(1):42-9. PubMed ID: 9481438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The transtubular potassium concentration in patients with hypokalemia and hyperkalemia.
    Ethier JH; Kamel KS; Magner PO; Lemann J; Halperin ML
    Am J Kidney Dis; 1990 Apr; 15(4):309-15. PubMed ID: 2321642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of compound mutations of SLC12A3 gene in a Chinese pedigree with Gitelman syndrome exhibiting Bartter syndrome-liked phenotypes.
    Dong B; Chen Y; Liu X; Wang Y; Wang F; Zhao Y; Sun X; Zhao W
    BMC Nephrol; 2020 Aug; 21(1):328. PubMed ID: 32758178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Regulation of kidney on potassium balance and its clinical significance].
    Xie QH; Hao CM
    Sheng Li Xue Bao; 2023 Apr; 75(2):216-230. PubMed ID: 37089096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does hypokalaemia cause nephropathy? An observational study of renal function in patients with Bartter or Gitelman syndrome.
    Walsh SB; Unwin E; Vargas-Poussou R; Houillier P; Unwin R
    QJM; 2011 Nov; 104(11):939-44. PubMed ID: 21705784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bartter-Gitelman syndromes].
    Blanchard A; Courand PY; Livrozet M; Vargas-Poussou R
    Nephrol Ther; 2020 Jul; 16(4):233-243. PubMed ID: 32622651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bartter- and Gitelman-like syndromes: salt-losing tubulopathies with loop or DCT defects.
    Seyberth HW; Schlingmann KP
    Pediatr Nephrol; 2011 Oct; 26(10):1789-802. PubMed ID: 21503667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transtubular potassium concentration gradient (TTKG) and urine ammonium in differential diagnosis of hypokalemia.
    Joo KW; Chang SH; Lee JG; Na KY; Kim YS; Ahn C; Han JS; Kim S; Lee JS
    J Nephrol; 2000; 13(2):120-5. PubMed ID: 10858974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different roles of the RAAS affect bone metabolism in patients with primary aldosteronism, Gitelman syndrome and Bartter syndrome.
    Tang W; Chai Y; Jia H; Wang B; Liu T; Wang H; Dai C
    BMC Endocr Disord; 2022 Feb; 22(1):38. PubMed ID: 35148746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bartter syndrome representing digenic-based salt-losing tubulopathies presumably accelerated by renal insufficiency.
    Umene R; Kitamura M; Arai H; Matsumura K; Ishimaru Y; Maeda K; Uramatsu T; Obata Y; Mori T; Sohara E; Uchida S; Nishino T
    CEN Case Rep; 2020 Nov; 9(4):375-379. PubMed ID: 32506365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indomethacin, amiloride, or eplerenone for treating hypokalemia in Gitelman syndrome.
    Blanchard A; Vargas-Poussou R; Vallet M; Caumont-Prim A; Allard J; Desport E; Dubourg L; Monge M; Bergerot D; Baron S; Essig M; Bridoux F; Tack I; Azizi M
    J Am Soc Nephrol; 2015 Feb; 26(2):468-75. PubMed ID: 25012174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Gitelman syndrome].
    Ungaro CM; Odstrcil-Bobillo MS; Russo PM
    Medicina (B Aires); 2020; 80(1):87-90. PubMed ID: 32044746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacological characteristics of molecular-based inherited salt-losing tubulopathies.
    Nozu K; Iijima K; Kanda K; Nakanishi K; Yoshikawa N; Satomura K; Kaito H; Hashimura Y; Ninchoji T; Komatsu H; Kamei K; Miyashita R; Kugo M; Ohashi H; Yamazaki H; Mabe H; Otsubo A; Igarashi T; Matsuo M
    J Clin Endocrinol Metab; 2010 Dec; 95(12):E511-8. PubMed ID: 20810575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transtubular potassium concentration gradient: a useful test to estimate renal aldosterone bio-activity in infants and children.
    Rodríguez-Soriano J; Ubetagoyena M; Vallo A
    Pediatr Nephrol; 1990 Mar; 4(2):105-10. PubMed ID: 2397174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Total body potassium, skeletal muscle potassium and magnesium in patients with Bartter's syndrome.
    Rudin A; Bosaeus I; Hessov I
    Scand J Clin Lab Invest; 1990 May; 50(3):273-7. PubMed ID: 2353156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gitelman syndrome.
    Park PG; Karet Frankl FE
    BMJ; 2012 May; 344():e3590. PubMed ID: 22645210
    [No Abstract]   [Full Text] [Related]  

  • 18. The effect of amiloride on the renin-aldosterone system in primary hyperaldosteronism and Bartter's syndrome.
    Griffing GT; Aurecchia SA; Sindler BH; Melby JC
    J Clin Pharmacol; 1982; 22(11-12):505-12. PubMed ID: 6761369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expert consensus for the diagnosis and treatment of patients with Gitelman syndrome].
    Gitelman Syndrome Collaborative Study Group
    Zhonghua Nei Ke Za Zhi; 2017 Sep; 56(9):712-716. PubMed ID: 28870047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of sodium chloride co-transporter impairs the outgrowth of the renal distal convoluted tubule during renal development.
    Schnoz C; Carrel M; Loffing J
    Nephrol Dial Transplant; 2020 Mar; 35(3):411-432. PubMed ID: 31436795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.